Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $55.87 Analyst target: $95.70 Upside: 71.29%
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. The company is headquartered in Carmel, Indiana.
See the full interactive analysis & chart →Informational only — not investment advice.